Podcasts about md phd

Physician entrepreneurship is quickly becoming a path forward for doctors looking to reclaim their time, purpose, and financial stability. In this episode, Dr. Christopher H. Loo, MD-PhD sits down with Dr. Pranay Parikh, MD, a practicing physician, podcast host, and real estate investor who exemplifies how physicians can thrive both inside and outside of clinical practice.Many doctors feel stuck trading time for money or are suffering from burnout in medicine. Whether you're a physician frustrated with rigid hospital systems or simply looking for a new challenge, Dr. Parikh's journey offers real answers. He speaks candidly about the power of launching side hustles for physicians, building passive income for doctors, and how to strategically pivot from doctor to entrepreneur—even with limited time.As co-founder of Ascent Equity and contributor to Passive Income MD, Dr. Parikh has helped thousands of physicians learn how to create financial freedom for physicians through scalable ventures like real estate syndication for doctors. If your search history includes “how do I leave medicine?” or “how can I earn more without more shifts?”, this episode was made for you.

In today's episode, supported by Thermo Fisher Scientific, we had the pleasure of speaking with Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP, about the FDA approval of the Oncomine DX Express Test for use as a companion diagnostic for sunvozertinib (Zegfrovy) in EGFR exon 20 insertion mutation–positive non–small cell lung cancer and for use in tumor profiling. Dr Ganti is a professor in the University of Nebraska Medical Center (UNMC) Division of Oncology & Hematology, the Dr. and Mrs. D. Leon UMNC Research Fund Chair in Internal Medicine, and the associate director for Clinical Research at the Fred & Pamela Buffett Cancer Center in Omaha. Dr Cushman is the Henry F. Krous Professor of Pathology, a professor in the UNMC Department of Pathology, Microbiology and Immunology, director of the Division of Diagnostic Molecular Pathology and Human Genetics, medical director of the Molecular Diagnostics and Personalized Medicine Laboratory at Nebraska Medicine, director of the Molecular Genetic Pathology Fellowship Program, and associate director of the UMNC MD-PhD Scholars Program.  In our exclusive interview, Drs Ganti and Cushman discussed the significance of the launch of the Oncomine DX Express Test, the benefits and limitations of rapid next-generation sequencing, and features that set Oncomine DX apart from other available tests. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Turning down that med school acceptance might cost more than you think. Listener “my initials are ARM” got into medical school—cue the confetti—but now that reality's set in, she's not feeling great about her only acceptance. The school is small, expensive, and far from home. Should she go anyway or risk reapplying in hopes of a better fit next year? MD/PhD students Michael Arrington, Shruthi Kondaboina, Jessica Smith, and M1 Maria Schapfel weigh the real costs of walking away from an acceptance, from the red flags admissions committees look for to the gamble of getting in again. They get honest about finances, family, and the very unsexy truth about how much the campus “vibe” actually matters. Plus, what to say if you do it anyway. Bonus: the MD/PhD students dish about why they took that road, while Maria counters with why MD is better for her.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Catharine Young, PhD, who is currently a senior fellow at the Harvard T. H. Chan School of Public Health. Young was formerly the assistant director of Cancer Moonshot Policy and International Engagement in the White House Office of Science and Technology Policy in Washington, DC. Camidge and Young, a South African–born scientist, discussed Young's journey from Johannesburg to Charlotte, North Carolina. Young shared that after undergrad, where she majored in biology, she joined a post-baccalaureate fellowship at the National Institute of Alcoholism and Alcohol Abuse, sparking her passion for research. This led her to pursue a PhD in biomedical sciences at the University of Missouri, focusing on the brain's role in regulating blood pressure. Catherine noted the challenges of changing labs mid-PhD and her eventual decision to step away from academia. During her postdoc, Young was inspired by her advisor's science policy fellowship, leading her to pursue a fellowship herself. She was matched with the US Department of Defense, working on chemical and biological threat reduction in former Soviet states and West Africa during the Ebola outbreak. Though she described the experience was eye-opening, she eventually shifted career paths, realizing that long-term government work wasn't the right fit for her career goals. From there, Young worked for the British Embassy in Washington, DC, bridging UK and US science priorities. She then joined the Biden Cancer Initiative, continuing the Cancer Moonshot's momentum through its ups and downs. Young reflected on how her variety of experiences led her to launch the Cancer Moonshot to new heights as she worked to advance cancer research and patient care through cancer-related policy and global engagement. Young concluded by highlighting her passion for continuing to expand medical treatment access worldwide.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Catharine Young, PhD, who is currently a senior fellow at the Harvard T. H. Chan School of Public Health. Young was formerly the assistant director of Cancer Moonshot Policy and International Engagement in the White House Office of Science and Technology Policy in Washington, DC. Camidge and Young, a South African–born scientist, discussed Young's journey from Johannesburg to Charlotte, North Carolina. Young shared that after undergrad, where she majored in biology, she joined a post-baccalaureate fellowship at the National Institute of Alcoholism and Alcohol Abuse, sparking her passion for research. This led her to pursue a PhD in biomedical sciences at the University of Missouri, focusing on the brain's role in regulating blood pressure. Catherine noted the challenges of changing labs mid-PhD and her eventual decision to step away from academia. During her postdoc, Young was inspired by her advisor's science policy fellowship, leading her to pursue a fellowship herself. She was matched with the US Department of Defense, working on chemical and biological threat reduction in former Soviet states and West Africa during the Ebola outbreak. Though she described the experience was eye-opening, she eventually shifted career paths, realizing that long-term government work wasn't the right fit for her career goals. From there, Young worked for the British Embassy in Washington, DC, bridging UK and US science priorities. She then joined the Biden Cancer Initiative, continuing the Cancer Moonshot's momentum through its ups and downs. Young reflected on how her variety of experiences led her to launch the Cancer Moonshot to new heights as she worked to advance cancer research and patient care through cancer-related policy and global engagement. Young concluded by highlighting her passion for continuing to expand medical treatment access worldwide.

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Anna Maria Geretti, MD, PhD - Understanding an Individual's Readiness for Long-Acting Injectable Therapy

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

In this episode, Hanya Oversby sat down with Dr. @kyuhoi —board-certified physician at the recent Non Surgical Symposium on the Gold Coast, Australia.Dr Yi is a PhD anatomist, and internationally recognized expert in aesthetic medicine. Based in Seoul, Korea, Dr. Yi shares how his dual roles in clinical practice and research have shaped a uniquely precise approach to cosmetic procedures.Dr Yi and Hanya dive into the importance of procedural anatomy, the evolution of botulinum toxin and filler techniques, and the future of ultrasound-guided interventions.Whether you're a practitioner, student, or simply curious about the science behind beauty, this episode offers an expert's view into the intersection of anatomy, innovation, and artistry.For more information on Dr Yi, please click on this linkhttps://www.researchgate.net/profile/Kyu-Ho-Yi More information about Hanya Oversby can be found onhttps://hanyaoversby.com.au/ #medicalworld #doctordiariespodcast#hanyaoversby #kyuhoi #podcast #medicalbusiness #doctorsofinstagram #aestheticworld#doctor #secretsource Doctor Diaries is a podcast series designed for healthcare professionals, featuring in-depth interviews with experienced clinicians across medical aesthetics, dermatology, surgery, and integrative medicine. Each episode provides insights into clinical approaches, practice development, and the realities of patient care in today'sregulatory landscape.This content is intended for qualified healthcare professionals only and may discuss prescription-onlyproducts, regulated procedures, and clinical experiences not suitable for general public promotion. Always refer to relevant professional guidelines and product information.

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Anna Maria Geretti, MD, PhD - Understanding an Individual's Readiness for Long-Acting Injectable Therapy

Financial freedom is the dream of many professionals—but few achieve it as strategically and successfully as Dr. Christopher H. Loo, MD-PhD. In this episode, Chris shares his journey from physician to early retiree at 38, diving deep into the mindset and investment tactics that led him there.Along the way, we explore the importance of passive income, building multiple streams of income, and how real estate investing during the 2008 crash set Chris on a path to lasting wealth. He also discusses the power of digital entrepreneurship, creating a personal brand, and how index funds investing can create long-term security—even for high-income professionals like physicians.If you're searching for a roadmap to early retirement, wondering how to create time freedom without sacrificing your profession, or want to escape the rat race through smart financial decisions, this interview gives you answers and insights. Chris's experience bridges the gap between ambition and action, offering solutions that align with what freedom-seekers are looking for in today's economy.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Gregory Hawryluk, MD, for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Dr. Hawryluk is a neurosurgeon with a PhD in stem cell research. He is the Medical Director of the Brain Trauma Foundation. As we began our 30-minute discussion, Dr. Hawryluk described his medical training as a neurosurgeon. He explained the origin and goals of the Brain Trauma Foundation.  According to Dr. Hawryluk, the Brain Trauma Foundation's most significant contribution has been developing clinical practice evidence-based guidelines for traumatic brain injury. These guidelines have been associated with a 50% reduction in head injury mortality. Dr. Hawryluk suggested that the guidelines serve as a basis for individualized care that may lead to even greater benefits. The guidelines are available on the Brain Trauma Foundation's website. We explored the definition of concussion and current approaches to management. Dr. Hawryluk explained that neuroimaging, such as CT and MRI, should be normal in a patient with concussion. He offered his opinion regarding the safety of participating in contact sports, which may result in concussions. We also broached the subject of chronic traumatic encephalopathy (CTE). To learn more, please contact The Brain Trauma Foundation: https://braintrauma.org/#concussion #CTE #traumatic brain injury #TBI@braintraumafoundationPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Remember when we used to use stacked shocks for ventricular arrhythmias or load patients up with high doses of epinephrine and bicarb? Over the last 25 years, resuscitation guidelines have evolved and it's our job to stay updated on the current protocols.Here to help us break down what's changed and what still works is Dr. Ashish Panchal, Chair of Emergency Cardiovascular Care for the AHA and host of the In the Heart of Care podcast. We discuss how a common cardiac arrest scenario would be treated from 2000 to today, highlighting key guideline changes like the shift to neuroprotective strategies, high-quality CPR, and post-arrest care.Tune in to stay current and hear how science continues to shape the way we save lives!Topics discussed in this episode:How AHA guidelines are developedDr. Panchal's research and impactEarly 2000s resuscitation guidelines“Save the brain” approach in the 2010sHow medication use has evolved, like epinephrineThe current focus on high-performance CPR and neuroprotective strategiesPost-arrest care and survivorshipBalancing clinical trends with scientific validationHow nurses can stay current on AHA guidelinesCheck out the In the Heart of Care Podcast here:https://rqipartners.com/podcast/Mentioned in this episode:CONNECT

Join host Geoffrey Rubin, MD, MBA, FACR, for a candid and wide-ranging conversation with Mitchell D. Schnall, MD, PhD, FACR—Professor of Radiology and Senior Vice President for Data and Technology Solutions at Penn Medicine. A highly accomplished radiology researcher and leader, Dr. Schnall served for 12 years as Vice Chair for Research in the Department of Radiology at the University of Pennsylvania, followed by another 12 years as Chair. His national leadership includes serving as Chair of ACRIN and the ACR Commission on Research, as well as President of the Academy for Radiology and Biomedical Imaging Research. His research contributions have earned him election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. In this episode, Dr. Schnall reflects on his journey—from a curious kid with a ham radio license and an Ivy League gymnast to a nationally recognized leader in academic radiology. He shares how his background in physics and engineering shaped his hands-on approach to problem-solving, innovation, and leadership—including his early work developing MRI coils and his unexpected path into breast imaging research. Dr. Schnall also discusses lessons from his time leading Penn Radiology, his philosophy on team building and faculty development, and why embracing discomfort, trusting others, and taking smart risks are essential traits for effective leadership. With humility, clarity, and a touch of humor, Dr. Schnall offers valuable insights into the realities of leading in academic medicine, the importance of intellectual generosity, and the power of staying curious throughout one's career. Don't miss this thoughtful conversation with a leader who continues to shape the future of radiology—while never losing sight of the joy in figuring things out. Behind the Mic! Dr. Schnall and his wife have been married for 37 years. Together, they have a 32-year-old daughter, a 29-year-old son, and an 11-month-old granddaughter! When he's not working, Dr. Schnall loves to take things apart and put them back together. He is a serious “DIYer”, having renovated his own kitchen and multiple bathrooms at his home. He also enjoys riding his bicycle and eating spicey hot peppers!

In this inspiring episode of the BioBuilder Podcast, Dev and Joshua, co-founders of the startup AIVON, take listeners through their personal journeys of curiosity, innovation, and social impact. The conversation weaves through their formative experiences with science and technology, their time in the BioBuilderClub, and their ambitious venture into the world of AI-powered healthcare. Origins of Scientific CuriosityDev recounts how growing up in a science-loving household, with parents and an aunt deeply engaged in the subject, laid the groundwork for his fascination. From tinkering with technology alongside his dad to wondering about disease mechanisms, he developed an early love for biology and engineering. This curiosity eventually led him to Alliance Academy, where he joined the BioBuilder Club, a decision that would define much of his scientific identity. The BioBuilder ExperienceAs part of the BioBuilder program, Dev and his team designed a sustainable biofiltration system that uses genetically engineered bacteria (E. coli, Bacillus subtilis, and Pseudomonas putida) to remove heavy metals from water. The bacteria were enhanced with plasmids encoding metal-detoxifying enzymes and embedded in a biochar-based medium for stability and efficiency. Their modular, scalable filter design bridged biology and engineering in a way that was both educational and impactful. Dev credits BioBuilder for teaching him adaptability, technical rigor, and how to bring abstract ideas to life. Collaboration & DiscoveryThe episode explores how Dev collaborated with peers to develop their project, noting “aha!” moments when the science began to click. The iterative nature of their work, coupled with expert guidance from mentors like Dr. Grace Vezeau and Ms. Caroline Matarrese, helped deepen their understanding of real-world science. Soft skills like communication and teamwork were just as vital as technical prowess, a lesson Dev carries into his startup journey into career paths, possibly through an MD-PhD program.Building AIVON and MedisenseShifting to the theme of innovation, Dev and Joshua introduce their startup AIVON, based in Atlanta. Their flagship product, MediSense, is an AI-powered diagnostic platform that allows users to input symptoms and receive real-time health assessments. The idea was born from the intersection of their scientific training and the urgent need for accessible, intelligent healthcare tools.They share how conversations with patients, doctors, and mentors shaped MediSense's design and functionality, emphasizing the importance of user feedback in product development. Their goal is to make fast, affordable, and intelligent diagnostics available to everyone, especially in underserved areas. Despite challenges—from building the tech to managing startup logistics—they remain focused on scaling the product and seeking potential partnerships with hospitals and schools.Learn more about BioBuilder's programs for students, educators, and industry professionals here

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Luis Querol, MD, PhD - 2025 Congress Highlights From Edinburgh, Scotland: Breaking Down the Data Driving Novel Therapeutic Developments in CIDP

In S6 E5 I am delighted to welcome Dr Colin West MD PhD to the podcast. Dr West is a practising physician, educator, biostatistician and he is globally renowned for his research in professional and organisational wellbeing in healthcare. He has been deeply embedded in research work in this area with colleagues at Mayo Clinic for over two decades to advance and inform healthcare organisational and clinician wellbeing leadership, strategy and evidence-informed system and work unit interventions to promote physician wellbeing and reduce distress. Dr West is the inaugural program director for physician wellbeing at Mayo Clinic. He is the recipient of multiple awards for his research and education work and collaborates extensively with scientists and groups within and outside Mayo Clinic. External collaborations include members of leadership in the American Medical Association. His work with colleagues including Dr Tait Shanafelt has  been published in multiple top-tier journals, including the Lancet, the Journal of the American Medical Association, Annals of Internal Medicine, and JAMA Internal Medicine.   In this conversation we discuss the evolution of his work over the past two decades. We learn how the combination of unique skills, intellectual curiosity and a deep investment and sense of purpose led to a critical coalition of colleagues who have helped to advance and build evidence-informed road maps and organisational blueprints  to promote physician wellbeing and professional satisfaction and reduce burnout and distress. I was particularly keen to explore some of the key intervention studies including the COMPASS trail ( Colleagues Meeting to Promote and Sustain Satisfaction) and the research about leadership capability and coaching/development. This episode is full of both the science and practical wisdom Dr West brings as a clinical expert in this field and yet still scratches the surface of his work.  A lot of his efforts today centre on attention to the MVPs ( meaning values and purpose )of professional wellbeing for his colleagues and the work they do in turn for their patients. He finishes with a powerful call to action at this juncture and critical inflection point for healthcare and clinicians globally. This is fundamentally important work and I am grateful to Colin and colleagues for continuing to advance our knowledge and applied practice. Links/References/ResourcesDr West's Wellbeing Wednesday Thread https://www.linkedin.com/posts/colin-west-57821b82_colin-west-colinwestmdphd-on-x-activity-7252370843236749312-1WMg/https://www.mayo.edu/research/faculty/west-colin-p-m-d-ph-d/bio-00027800https://edhub.ama-assn.org/steps-forward/pages/professional-well-beingThe COMPASS Trial https://pubmed.ncbi.nlm.nih.gov/34366134/Register for the Australasian Doctors' Health conference to continue to the conversation in 2025:https://adhc.org.au/The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VZA865. CME/MOC/AAPA credit will be available until June 29, 2026.Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy & Targeted Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Incyte Corporation, Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VZA865. CME/MOC/AAPA credit will be available until June 29, 2026.Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy & Targeted Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Incyte Corporation, Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VZA865. CME/MOC/AAPA credit will be available until June 29, 2026.Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy & Targeted Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Incyte Corporation, Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VZA865. CME/MOC/AAPA credit will be available until June 29, 2026.Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy & Targeted Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Incyte Corporation, Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VZA865. CME/MOC/AAPA credit will be available until June 29, 2026.Refining Treatment Models For Biliary Tract Cancer Aligning Practice With Rapidly Evolving Evidence on Immunotherapy & Targeted Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Incyte Corporation, Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.

Send us a textIn this episode of At the Bench, Drs. Misty Good and Betsy Crouch welcome Dr. Amélie Collins, an R01-funded neonatologist and associate professor at Cincinnati Children's. A classically trained immunologist turned hematopoietic stem cell biologist, Dr. Collins shares her journey from philosophy major at the University of Chicago to leading a research program focused on fetal myelopoiesis in the context of maternal inflammation.She discusses her training path through MD/PhD at NYU, her formative time in the labs of Dan Littman and Emmanuelle Passegué, and the critical mentorship moments that shaped her career. Dr. Collins offers an honest look at the challenges and joys of long training, pivoting research directions, and starting an independent lab. She reflects on the intersection of science and clinical care, grant writing as a creative exercise, and the importance of celebrating effort and submission, not just success.We also dive into her Cell paper on the extrinsic regulation of emergency myelopoiesis in the fetus, the role of maternal IL-10, and how her lab is exploring how hematopoietic stem cells mature and retain memory of early-life exposures.Dr. Collins leaves listeners with powerful advice: “Do it because you love it. This career demands a lot, including your time, energy, and weekends. But if you love it, it's worth it.”As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In today's episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in pretreated patients with HER2-mutated non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine. In our exclusive interview, Dr Nagasaka discussed current second-line treatment standards for patients with HER2-mutated NSCLC, how the use of T-DXd in this setting may evolve with the emergence of investigational agents, and the importance of integrating HER2 immunohistochemistry testing into clinical practice.

Prof. (Dr.) Tirath Das Dogra, MD, FAMS, FICPath is India's best-known forensic pathologist and a former Director of the All India Institute of Medical Sciences (AIIMS), New Delhi. Awarded the country's first MD in Forensic Medicine (AIIMS, 1976) and later head of the department (1987-2012), he set up AIIMS's pioneering Medical Toxicology Laboratory (1987) and the institute's first hospital-based DNA profiling facility (1991), which solved Delhi's inaugural DNA-evidence criminal case in 1992.Prof. Dogra led the post-mortem of Prime Minister Indira Gandhi, deposed in her assassination trial, and has provided expert evidence or crime-scene reconstruction in many of modern India's most watched investigations—Nithari serial killings, Tandoor murder, Aarushi-Hemraj double homicide, Bilkis Bano case, Gujarat “fake” encounters, Batla House shoot-out and more.A prolific scholar, he has authored/edited 200+ papers and the Indian edition of Lyon's Medical Jurisprudence, guided over fifty MD/PhD theses, evolved the field technique now known as “Dogra's Test” for detecting old bullet marks, and introduced 3-D forensic animation to Indian courts.Post-retirement he became founding Vice-Chancellor of SGT University, Haryana, and continues to lecture worldwide on forensic science, medico-legal ethics and criminal psychology.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CEH865. CME/AAPA credit will be available until July 3, 2026.Alzheimer's Disease Neuroradiology Case Conference: Mastering the New Frontier in Diagnosis and Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CEH865. CME/AAPA credit will be available until July 3, 2026.Alzheimer's Disease Neuroradiology Case Conference: Mastering the New Frontier in Diagnosis and Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CEH865. CME/AAPA credit will be available until July 3, 2026.Alzheimer's Disease Neuroradiology Case Conference: Mastering the New Frontier in Diagnosis and Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Politically-driven chaos is disrupting U.S. scientific institutions and creating challenges for science in Canada. Science is a global endeavour and collaborations with the U.S. are routine. In this special episode of Quirks & Quarks, we explore what Canadian scientists are doing to preserve their work to assert scientific sovereignty in the face of this unprecedented destabilization. Canadian climate scientists brace for cuts to climate science infrastructure and data U.S. President Donald Trump's attacks on climate science are putting our Earth observing systems, in the oceans and in orbit, at risk. Canadian scientists who rely on U.S. led climate data infrastructure worry about losing long-term data that would affect our ability to understand our changing climate. With: Kate Moran, the president and CEO of Ocean Networks Canada and Emeritus Professor of Oceanography at the University of Victoria Debra Wunch, Physicist at the University of TorontoChris Fletcher, Department of Geography and Environmental Management at the University of WaterlooU.S. cuts to Great Lakes science and monitoring threaten our shared freshwater resourceU.S. budget and staffing cuts are jeopardizing the long-standing collaboration with our southern neighbour to maintain the health of the Great Lakes, our shared resource and the largest freshwater system in the world. With: Jérôme Marty, executive director of the International Association for Great Lakes Research and part-time professor at the University of OttawaGreg McClinchey, policy and legislative director with the Great Lakes Fishery CommissionMichael Wilkie, Biologist at Wilfred Laurier UniversityBrittney Borowiec, research associate in the Wilkie Lab at Wilfred Laurier UniversityAaron Fisk, Ecologist and Canada Research Chair at the University of WindsorUnexpected ways U.S. culture war policies are affecting Canadian scientists One of the first things President Trump did after taking office was to sign an executive order eliminating all DEI policies in the federal government. This is having far-reaching consequences for Canadian scientists as they navigate the new reality of our frequent research partner's hostility against so-called “woke science.”With:Dr. Sofia Ahmed, Clinician scientist, and academic lead for the Women and Children's Health Research Institute at the University of Alberta Angela Kaida, professor of health sciences and Canada Research Chair at Simon Fraser University in VancouverDawn Bowdish, professor of immunology, the executive director of the Firestone Institute for Respiratory Health and Canada Research Chair at McMaster UniversityKevin Zhao, MD/PhD student in immunology in the Bowdish Lab at McMaster UniversityJérôme Marty, executive director of the International Association for Great Lakes ResearchCanada has a ‘responsibility' to step up and assert scientific sovereigntyA 2023 report on how to strengthen our federal research support system could be our roadmap to more robust scientific sovereignty. The Advisory Panel on the Federal Research Support System made recommendations to the federal government for how we could reform our funding landscape. The intent was to allow us to quickly respond to national research priorities and to make Canada a more enticing research partner in world science. With: Frédéric Bouchard, Dean of the Faculty of Arts and Sciences and professor of philosophy of science at the Université de Montreal. Chair of the Advisory Panel on the Federal Research Support System.